Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NDO’s surgical device found effective against GERD
At five-years post procedure, 67% of patients who required daily PPI’s prior to receiving Plicator treatment remained off daily PPI therapy and gastroesophageal reflux disease (GERD) HRQL scores
At five-years post procedure, 67% of patients who required daily PPI’s prior to receiving Plicator treatment remained off daily PPI therapy and gastroesophageal reflux disease (GERD) HRQL scores
In this study, a single injection of CBLB612 was given in combination with the current standard methodology for stem cell donor isolation, which is four daily injections of
Genentech and Roche are collaborating on development of the antibody which selectively blocks the interaction of the OX40 ligand and its receptor. The companies are evaluating the antibody
The Neurologix procedure delivers a gene (glutamic acid decarboxylase, or GAD) to the subthalamic nucleus of the brain, where it makes an inhibitory neurotransmitter called GABA that helps
The FDA committee voted against approval of tedisamil, at this time, requesting Solvay Pharmaceuticals to provide additional information to the Agency. While not binding, the Committee’s recommendations will
Fast Track designation is reserved for new drugs that demonstrate the potential to address an unmet medical need and are intended for the treatment of a serious or
The data showed that a viral microRNA (miR-K12-11), which is encoded by KSHV, functions as a mimic of the host cell microRNA known as miR-155. Also, expression of
The product portfolio consists of well-established pharmaceuticals such as Kavepenin, Heracillin, Kalcipos, and TrioBe. The acquisition is said to strengthen Meda’s home base in Sweden, and new product
ISIS 333611 is a second-generation antisense drug in development for the treatment of amyotrophic lateral sclerosis (ALS) through the inhibition of Cu/Zn superoxide dismutase, a molecule that is
This multicenter, randomized, open-label Phase II study of IMC-1121B is enrolling patients with metastatic malignant melanoma who have not received prior chemotherapy for the disease. A total of